Menu
The Goodman Institute Health Blog
  • Home
  • Authors
    • Devon Herrick, Ph.D.
    • John C. Goodman
  • Popular Topics
    • Artificial Intelligence and Healthcare
    • Consumer-Driven Health Care
      • Affordable Care Act
      • Cost of Healthcare
      • COVID-19 and Public Health
      • Doctors & Hospitals
      • Public Insurance
      • Policy & Legislation
    • Direct Primary Care
    • Health Economics & Costs
      • Drug Prices & Regulations
      • Health Insurance
      • Health Reform
    • Medical Tourism
    • Telemedicine
    • Medicare
      • Single-Payer/Medicare-for-All
  • Goodman Institute
  • Contact
The Goodman Institute Health Blog

Thursday Links

Posted on August 31, 2023August 30, 2023 by John C. Goodman

Pharma: Medicare drug price negotiation could slow the search for a cure for cancer.

Good summary of the case against Medicare price negotiation.

Economic freedom is positively correlated with civic virtue.

Countries with the highest economic growth rates have the lowest birth rates.

Skip the next business meeting: Google Meet video lets you send a bot to attend the meeting on your behalf.

The U.S. has at least 600 fewer nursing homes than it did six years ago.

3 thoughts on “Thursday Links”

  1. Bob Hertz says:
    August 31, 2023 at 12:55 pm

    I am skeptical of the claim above by a U of Chicago economist that price reductions on Medicare drugs will lead to a loss of $18 trillion in GDP.

    If fewer drugs are produced for the Medicare market, this could lead to lower life expectancy for seniors. As a senior myself, I am not overjoyed by that….but my untutored question is, “Why does that hurt the economy?”

    When seniors live longer, they hold onto to their money, improve their homes, buy cars, and go into nursing homes.

    If seniors die a little sooner, their kids get money sooner and they buy homes, et al et al.

    I don’t see why GDP would fall at all.

    The Daily Signal is a libertarian and conservative publication and I can understand why they want to bash the federal government.

    But I am not sure they are right on the economics.

    Loading...
    Reply
  2. Bart Ingles says:
    September 1, 2023 at 12:19 pm

    The Economist ran a couple if interesting articles this week. There was a leader titled, “America’s new drug-pricing rules have perverse consequences,” and another in the business section, “America’s plan to cut drug prices comes with unpleasant side-effects.”

    The gist was that the new rules would likely stifle development of small molecule drugs in favor of injectable, large molecule “biologics,” and that manufacturers will likely delay new drug introduction for small patient populations with rare or end-stage conditions, until the drug is approved for the largest markets, in order to game the pricing clock.

    Loading...
    Reply
  3. Bob Hertz says:
    September 1, 2023 at 12:52 pm

    If a price reduction on a drug for rheumatoid arthritis benefits 2 million seniors — and the cost is a delay on a specialty drug for 9,000 sufferers from a rare blood disorder….well, I would consider that an acceptable trade-off.

    I am not a fan of perfectionist public policy.

    Loading...
    Reply

Join the conversation.Cancel reply

For many years, our health care blog was the only free enterprise health policy blog on the internet. Then, when the NCPA closed its doors, the health blog stopped as well.

During this five-year hiatus no one else has come forward to claim the space. So, my colleagues and I have decided to restart the blog in connection with the Goodman Institute. We invite you and others to use this forum to share your views.

John C. Goodman,

Visit www.goodmaninstitute.org

Subscribe via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 40 other subscribers

Popular Topics

©2025 The Goodman Institute Health Blog | Website by Lexicom
%d